Cisplatin liver toxicity
WebNov 7, 2024 · Hence, higher mitochondrial content directly correlates with sensitivity to cisplatin induced apoptosis. As mitochondrial reactive oxygen species are known to be toxic, we next analyzed the... WebFeb 2, 2024 · The liver is an important central organ for metabolism and detoxification in the human body and is susceptible to many factors, such as excessive alcohol consumption, hepatoviruses, various toxins, and drugs, leading to the development of liver diseases. ... Toxicity of Cisplatin to the central Nervous System of Male Rabbits. Bter 74 (3), 223 ...
Cisplatin liver toxicity
Did you know?
WebIts stereoisomer transplatin does not have any toxicity at equimolar concentrations, and it also possesses little antitumor activity. In this study, subcellular localization of both the platinum isomers was examined in the liver and kidney of the mouse 24 hours following the drug administration. WebOct 26, 2005 · It is possible that cisplatin-induced oxidative stress and CYP2E1-mediated oxidative stress synergize to produce hepatotoxicity. In the present study, the effect of increased CYP2E1 expression on cisplatin-induced hepatotoxicity was investigated.
WebCisplatin may be inadvisable if you have a history of severe allergic reaction to cisplatin, carboplatin, other platinum-containing formulations or mannitol. Do not receive any kind … WebToxicity evaluation study confirmed the safety profile of this combination therapy as OA in the dual-loaded NP system greatly reduced the cisplatin-induced hepatotoxicity. These results demonstrated that CDDP/OA-LCC NPs is an ideal approach in dealing with HCC alongside keeping the cisplatin toxicity parameters in check.
WebCis-platin is an effective anti-neoplastic agent, but it is also highly nephrotoxic. Here, we clearly identify the human organic cation transporter 2 (hOCT2) as the critical transporter for cis-platin nephrotoxicity in isolated human proximal tubules and offer a potential mechanism for reducing nephrotoxicity in clinical practice. WebAn association between cisplatin administration and hepatotoxicity is proposed in this patient. Conclusions: This patient may have experienced cisplatin-induced liver …
WebSome articles have reported severe toxicities induced by cisplatin/5-fluorouracil regimens, nevertheless, severe and lethal liver toxicity has not been previously reported. In this article, we report the case of a 72-year-old woman, who developed fulminant hepatitis, hypoglycemia and hypotension with atrial fibrillation not responding to treatment.
WebWorld Health Organization cirstin wongWebThe heart, liver, lungs, spleen, and kidneys were histologically analyzed 30 days after injection with the indicated concentrations of the nano-zinc carrier. Some chronic toxicity was observed in the 10 mg/kg/d group, mainly in the liver and kidney (Figure S2B). Therefore, a concentration of 5 mg/kg/d was used in subsequent studies. cirsten w youtubeWebDec 20, 2024 · Potential interactions between the liver and chemotherapy fall into two categories: Direct chemotherapy-induced hepatotoxicity. Potentiation of preexisting … diamond painting snowmanWeb2 days ago · LiverTox®provides up-to-date, unbiased and easily accessed information on the diagnosis, cause, frequency, clinical patterns and management of liver injury … cirs testsWebCisplatin (CP) is a potent and extensively used chemotherapeutic agent. There is paucity of literature involving role of mitochondria in mediating CP-induced hepatic toxicity, and its underlying mechanism remains unclear. Oxidative stress is a well-established biomarker of the mitochondrial toxicity. diamond painting smyth toysWebCisplatin has demonstrated efficacy against various types of cancers such as germ cell tumors, sarcomas, carcinomas as well as lymphomas. The current study presents a pharmacological review on the drug including its mechanism of action, resistance mechanism, and toxicity as well as its clinical applications. cirsten w try blueWebApr 12, 2024 · Currently, gemcitabine/cisplatin is first-line therapy for advanced iCCA based on the ABC-02 clinical trial (ClinicalTrials.gov identifier NCT02170090). That phase 3 study included 410 patients with locally advanced or metastatic CCA, gallbladder cancer, or ampullary cancer. cirstin caspary